KenTakeshitaMD

Physician

Dr. Takeshita is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
Yale-New Haven Medical CenterResidency, Internal Medicine, 1984 - 1986
Yale School of MedicineClass of 1983

PubMed

211 citations
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Thomas M. Habermann, Izidore S. Lossos, Glen Justice, Julie M. Vose, Peter H. Wiernik
British Journal of Haematology. 2009-05-01
60 citations
Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy
Beata Holkova, Kenichi Takeshita, Debbie M. Cheng, Matthew Volm, Carolyn Wasserheit
Journal of Clinical Oncology. 2001-09-15
204 citations
STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation.
Chien-Kuo Lee, Regina Raz, Ramon Gimeno, Rachel Gertner, Birte Wistinghausen
Immunity. 2002-07-01

AstraZeneca & Daiichi Sankyo’s TROPION-Breast01 Phase III Trial of Datopotamab Deruxtecan Fails to Achieve Statistical Significance Versus ChemotherapySeptember 24th, 2024
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III TrialSeptember 23rd, 2024
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 TrialSeptember 17th, 2024
Join now to see all